Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59, 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Singh J, Trabulsi EJ, Gomella LG. Is there an optimal management for localized prostate cancer? Clin. Interv. Aging5, 187–197 (2010).
   PubMed Web of Science ®Google Scholar
• Grubb RL, Kibel AS. High-risk localized prostate cancer: role of radical prostatectomy. Curr. Opin. Urol.20, 204–210 (2010).
   PubMedGoogle Scholar
• Garzotto M, Hung AY. Contemporary management of high-risk localized prostate cancer. Curr. Urol. Rep.11, 159–164 (2010).
   PubMedGoogle Scholar
• Stratton KL, Chang SS. Locally advanced prostate cancer, the role of surgical management. BJU Int.104, 449–454 (2009).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60, 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res.15, 4792–4798 (2009).
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol.23, 8253–8261 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol.8, 440–448 (2008).
   PubMed Web of Science ®Google Scholar
• Mohler JL. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab.22, 357–372 (2008).
   PubMedGoogle Scholar
• Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab.21, 315–324 (2010).
   PubMed Web of Science ®Google Scholar
• Agus DB, Cordon-Cardo C, Fox W et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl Cancer Inst.91, 1869–1876 (1999).
   PubMed Web of Science ®Google Scholar
• Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv. Exp. Med. Biol.617, 245–255 (2008).
   PubMedGoogle Scholar
• Culig Z, Bartsch G. Androgen axis in prostate cancer. J. Cell Biochem.99, 373–381 (2006).
   PubMed Web of Science ®Google Scholar
• Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal.6, e008 (2008).
   PubMedGoogle Scholar
• Centenera MM, Harris JM, Tilley WD, Butler LM. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol.22, 2373–2382 (2008).
   PubMed Web of Science ®Google Scholar
• Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol.21, 2855–2863 (2007).
   PubMed Web of Science ®Google Scholar
• Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J. Biol. Chem.282, 25801–25816 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Q, Li W, Zhang Y et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell138, 245–256 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Q, Li W, Liu XS et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell27, 380–392 (2007).
   PubMed Web of Science ®Google Scholar
• Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem.271, 6379–6388 (1996).
   PubMed Web of Science ®Google Scholar
• Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J. Urol.182, 2232–2241 (2009).
   PubMed Web of Science ®Google Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer8, 268–278 (2008).
   PubMed Web of Science ®Google Scholar
• Jia L, Berman BP, Jariwala U et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One3, e3645 (2008).
   PubMedGoogle Scholar
• Lupien M, Brown M. Cistromics of hormone-dependent cancer. Endocr. Relat. Cancer16, 381–389 (2009).
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science310, 644–648 (2005).
   PubMed Web of Science ®Google Scholar
• Lin C, Yang L, Tanasa B et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell139, 1069–1083 (2009).
   PubMed Web of Science ®Google Scholar
• Mani RS, Tomlins SA, Callahan K et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science326, 1230 (2009).
   PubMed Web of Science ®Google Scholar
• Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res.69, 6027–6032 (2009).
   PubMed Web of Science ®Google Scholar
• Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat. Rev. Urol.6, 429–439 (2009).
   PubMed Web of Science ®Google Scholar
• Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl Acad. Sci. USA106, 12465–12470 (2009).
   PubMed Web of Science ®Google Scholar
• Hunter J. Observations on certain parts of the animal oeconomy. In: The Complete Works of John Hunter. Palmer JF (Ed.). Haswell, Barrington & Haswell, PA, USA, 68 (1841).
   Google Scholar
• Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg.115, 1192–1200 (1942).
   PubMedGoogle Scholar
• Huggins C. The treatment of cancer of the prostate: (The 1943 address in surgery before the Royal College of Physicians and Surgeons of Canada). Can. Med. Assoc. J.50, 301–307 (1944).
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin.22, 232–240 (1972).
   PubMedGoogle Scholar
• Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab.22, 331–340 (2008).
   PubMed Web of Science ®Google Scholar
• Beekman KW, Hussain M. Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urol. Oncol.26, 415–419 (2008).
   PubMedGoogle Scholar
• Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol. Cell9, 601–610 (2002).
   PubMed Web of Science ®Google Scholar
• De Dosso S, Berthold DR. Docetaxel in the management of prostate cancer: current standard of care and future directions. Expert Opin. Pharmacother.9, 1969–1979 (2008).
   PubMedGoogle Scholar
• Sonpavde G, Sternberg CN. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. Int. J. Urol.17, 228–240 (2010).
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363, 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet376, 1147–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med.10, 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Donovan MJ, Osman I, Khan FM et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int.105, 462–467 (2010).
   PubMed Web of Science ®Google Scholar
• Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv. Exp. Med. Biol.617, 223–234 (2008).
   PubMedGoogle Scholar
• Ford OH 3rd, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol.170, 1817–1821 (2003).
   PubMed Web of Science ®Google Scholar
• Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J. Steroid Biochem. Mol. Biol.92, 255–264 (2004).
   PubMed Web of Science ®Google Scholar
• Waltering KK, Helenius MA, Sahu B et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res.69, 8141–8149 (2009).
   PubMed Web of Science ®Google Scholar
• Wang LG, Johnson EM, Kinoshita Y et al. Androgen receptor overexpression in prostate cancer linked to Pur α loss from a novel repressor complex. Cancer Res.68, 2678–2688 (2008).
   PubMedGoogle Scholar
• Li Y, Wang L, Zhang M et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res.69, 3332–3338 (2009).
   PubMed Web of Science ®Google Scholar
• Sharma A, Yeow WS, Ertel A et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest.120, 4478–4492 (2010).
   PubMed Web of Science ®Google Scholar
• Macleod KF. The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer? J. Clin. Invest.120, 4179–4182 (2010).
   PubMedGoogle Scholar
• Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol. Oncol.27, 251–257 (2009).
   PubMed Web of Science ®Google Scholar
• Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol.27, 36–41 (2009).
   PubMed Web of Science ®Google Scholar
• Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM. Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α,17β-diol to 5α-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol. Endocrinol.20, 444–458 (2006).
   PubMed Web of Science ®Google Scholar
• Penning TM, Steckelbroeck S, Bauman DR et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol. Cell Endocrinol.248, 182–191 (2006).
   PubMed Web of Science ®Google Scholar
• Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res.68, 6407–6415 (2008).
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68, 4447–4454 (2008).
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res.66, 2815–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res.67, 5033–5041 (2007).
   PubMed Web of Science ®Google Scholar
• Geller J, Albert J, Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin. Oncol.15, 53–61 (1988).
   PubMed Web of Science ®Google Scholar
• Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell Endocrinol.295, 115–120 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, Labrie F. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis.10, 301–306 (2007).
   PubMedGoogle Scholar
• Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol.28, 1481–1488 (2010).
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.28, 1489–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Steinkamp MP, O’Mahony OA, Brogley M et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res.69, 4434–4442 (2009).
   PubMed Web of Science ®Google Scholar
• Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics10, 18–25 (2009).
   PubMed Web of Science ®Google Scholar
• Terada N, Shimizu Y, Yoshida T et al. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate70, 252–261 (2010).
   PubMedGoogle Scholar
• Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin. Chem.56, 1492–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA107, 16759–16765 (2010).
   PubMed Web of Science ®Google Scholar
• Sun S, Sprenger CC, Vessella RL et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest.120, 2715–2730 (2010).
   PubMed Web of Science ®Google Scholar
• Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res.69, 2305–2313 (2009).
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res.68, 5469–5477 (2008).
   PubMed Web of Science ®Google Scholar
• Hu R, Dunn TA, Wei S et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res.69, 16–22 (2009).
   PubMed Web of Science ®Google Scholar
• Ward RD, Weigel NL. Steroid receptor phosphorylation: assigning function to site-specific phosphorylation. Biofactors35, 528–536 (2009).
   PubMedGoogle Scholar
• Guo Z, Dai B, Jiang T et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell10, 309–319 (2006).
   PubMed Web of Science ®Google Scholar
• Mahajan NP, Liu Y, Majumder S et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl Acad. Sci. USA104, 8438–8443 (2007).
   PubMed Web of Science ®Google Scholar
• Popov VM, Wang C, Shirley LA et al. The functional significance of nuclear receptor acetylation. Steroids72, 221–230 (2007).
   PubMedGoogle Scholar
• Dirac AM, Bernards R. The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Mol. Cancer Res.8, 844–854 (2010).
   PubMedGoogle Scholar
• Xu K, Shimelis H, Linn DE et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell15, 270–282 (2009).
   PubMedGoogle Scholar
• Kaikkonen S, Jaaskelainen T, Karvonen U et al. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol. Endocrinol.23, 292–307 (2009).
   PubMedGoogle Scholar
• Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat. Rev.36, 492–500 (2010).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat. Rev.36, 177–184 (2010).
   PubMed Web of Science ®Google Scholar
• Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene29, 3208–3216 (2010).
   PubMed Web of Science ®Google Scholar
• Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-src and androgen receptor synergy. Cancer Res.71(3), 862–872 (2011).
   PubMedGoogle Scholar
• Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr. Relat. Cancer13, 979–994 (2006).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, de Bono JS. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J. Clin. Oncol.28, e560–e561, author reply e562 (2010).
   PubMedGoogle Scholar
• Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a Cancer and Leukemia Group B study. Clin. Cancer Res.13, 2030–2037 (2007).
   PubMed Web of Science ®Google Scholar
• Taplin ME, Regan MM, Ko YJ et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin. Cancer Res.15, 7099–7105 (2009).
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol.28, 1481–1488 (2010).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol.26, 4563–4571 (2008).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AHM, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol.2008, 4563–4571 (2010).
   Google Scholar
• De Bono JS, Attard G, Reid AH et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). J. Clin. Oncol.26 (2008) (Abstract 5005).
   PubMedGoogle Scholar
• Attard G, Reid AHM, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol.27, 3742–3748 (2009).
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Fizazi K et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double blinded placebo controlled Phase III study. Ann. Oncol.21, viii3 (2010).
   Google Scholar
• Vasaitis TS, Bruno RD, Njar VCO. CYP17 inhibitors for prostate cancer therapy. J. Steroid Biochem. Mol. Biol. DOI: 10.1016/j.jsbmb.2010.11.005 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324, 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS et al. Antitumor activity of MDV3100 in a Phase I/II study of castration-resistant prostate cancer (CRPC). J. Clin. Oncol.27 (2009) (Abstract 5011).
   Google Scholar
• Foster WR, Car BD, Shi H et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate71(5), 480–488 (2010).
   PubMedGoogle Scholar
• Narayanan R, Yepuru M, Szafran AT et al. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res.70, 842–851 (2010).
   PubMedGoogle Scholar
• Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell17, 535–546 (2010).
   PubMed Web of Science ®Google Scholar
• Baumann CK, Castiglione-Gertsch M. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva Ginecol.61, 517–539 (2009).
   PubMedGoogle Scholar
• Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. Arimidex Study Group. J. Clin. Oncol.14, 2000–2011 (1996).
   PubMed Web of Science ®Google Scholar
• Vasaitis T, Belosay A, Schayowitz A et al. Androgen receptor inactivation contributes to antitumor efficacy of 17α hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol. Cancer Ther.7, 2348–2357 (2008).
   PubMed Web of Science ®Google Scholar
• Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr.5, 61–74 (2010).
   PubMed Web of Science ®Google Scholar
• Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer-I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis.3, 84–93 (2000).
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res.10, 6847–6854 (2004).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yasunaga Y, Segawa T et al. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol.21, 825–830 (2002).
   PubMed Web of Science ®Google Scholar